vitro caco 2 cell permeability (ATCC)
ATCC is a verified supplier 
ATCC manufactures this product 
99
Structured Review
ATCC
vitro caco 2 cell permeability
Vitro Caco 2 Cell Permeability, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 15355 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vitro+caco+2+cell+permeability/Caco-2/pm40367121-48-1-12
Average 99 stars, based on 15355 article reviews
Vitro Caco 2 Cell Permeability, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 15355 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vitro+caco+2+cell+permeability/Caco-2/pm40367121-48-1-12
Average 99 stars, based on 15355 article reviews
vitro caco 2 cell permeability - by Bioz Stars,
2026-11
99/100 stars
Images
Related Articles
In Vitro:Article Title: Preclinical pharmacokinetics, metabolism, and disposition of NXE0041178, a novel orally bioavailable agonist of the GPR52 receptor with potential for treatment of schizophrenia and related psychiatric disorders. Article Snippet: The physico-chemical properties, protein binding, metabolism, permeability, transporter interactions, chemical toxicity, and drug-drug interaction potential of the novel GPR52 agonist NXE0041178 were characterised.. NXE0041178 demonstrated high cellular permeability, little interaction with efflux transporters P-gp and BCRP, and extensive brain exposure in rodent, consistent with its intended use in CNS disorders.. In vivo pharmacokinetic profiling in mouse, rat and monkey demonstrated that NXE0041178 was well-absorbed, with low clearance, a moderate volume-of-distribution and moderate terminal half-life. Permeability:Article Title: Preclinical pharmacokinetics, metabolism, and disposition of NXE0041178, a novel orally bioavailable agonist of the GPR52 receptor with potential for treatment of schizophrenia and related psychiatric disorders. Article Snippet: The physico-chemical properties, protein binding, metabolism, permeability, transporter interactions, chemical toxicity, and drug-drug interaction potential of the novel GPR52 agonist NXE0041178 were characterised.. NXE0041178 demonstrated high cellular permeability, little interaction with efflux transporters P-gp and BCRP, and extensive brain exposure in rodent, consistent with its intended use in CNS disorders.. In vivo pharmacokinetic profiling in mouse, rat and monkey demonstrated that NXE0041178 was well-absorbed, with low clearance, a moderate volume-of-distribution and moderate terminal half-life. |
